Status:
COMPLETED
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Lead Sponsor:
Palatin Technologies, Inc
Collaborating Sponsors:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Conditions:
Sexual Arousal Disorder
Eligibility:
FEMALE
21-70 years
Phase:
PHASE2
Brief Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a pa...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Post menopausal and in general good health
- In a stable relationship with a male partner for at least 6 months
- Willing to attempt sexual activity once a week with your partner
Exclusion
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00425256
Start Date
February 1 2006
End Date
May 1 2007
Last Update
February 23 2011
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Affiliated Research Center
Huntsville, Alabama, United States
2
Quality of Life Medical & Research Center, LLC
Tucson, Arizona, United States
3
University of California, Department of Family and Preventative Medicine
La Jolla, California, United States
4
Downtown Women's Health Care
Denver, Colorado, United States